US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.33

-0.0435-0.10%

Post-market: 46.020.6925+1.53%19:30 EDT

Volume:1K

Turnover:49.11K

Market Cap:124.97M

PE:- -

High:46.37

Open:45.39

Low:45.33

Close:45.37

52wk High:48.78

52wk Low:27.68

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.38

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Scholar Rock announces FDA approval of isembyld

Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million

Pharming wins FDA nod to extend Joenja use to younger APDS children

Wall Street Analysts Are Bullish on Top Healthcare Picks

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live

Video: Novartis slides after second recent drug development setback

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint

Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12

THOMSON REUTERS

Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class

THOMSON REUTERS

Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/LFSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.3275,"timestamp":1789156800000,"preClose":45.371,"halted":0,"volume":1074,"hourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"delay":0,"changeRate":-0.0009587622049327025,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Market Closed","change":-0.0435,"latestTime":"09-11 16:00:00 EDT","open":45.39,"high":46.37,"low":45.3275,"amount":49106.001516000004,"amplitude":0.022977,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":45.371,"sharesOutstanding":2657035,"nav":45.4,"aum":125169389,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":46.02,"preClose":45.3275,"latestTime":"19:30 EDT","volume":10,"amount":452.9875,"timestamp":1789169406017,"change":0.6925,"changeRate":0.015278,"amplitude":0},"volumeRatio":0.3761557674902608},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3761557674902608,"shares":2757035,"dividePrice":0,"high":46.37,"amplitude":0.022977,"preClose":45.371,"low":45.3275,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.3275,"eps":0,"divideRate":0,"volume":1074,"delay":0,"ttmEps":0,"open":45.39,"prevYearClose":36.6147,"prevWeekClose":46.1341,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":46.1466,"twentyDayClose":46.8217,"sixtyDayClose":40.4233},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","PSCH","IYH","LABU","TECB","MRNX","IEIH","LFSC","GNMX","BMED","SRRK","NVIB","RSPH","IBRN","BK4588","PINK","XLVX","SYNB","IBB","BK4139","THNR","MEDI","BK4585","TBXU","BBP","FRTY","MRNY","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666216574","title":"Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2666216574","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666216574?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:00","pubTimestamp":1789160417,"startTime":"0","endTime":"0","summary":"Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employeesTravere Therapeutics granted inducement restricted stock units covering 56,220 common shares to 16 new employees o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL3z9S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574294","title":"Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574294?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:00","pubTimestamp":1789160400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA4L90NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666714225","title":"Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666714225","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666714225?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:06","pubTimestamp":1789157186,"startTime":"0","endTime":"0","summary":"Travere Therapeutics director Jeffrey A. Meckler disposes of common shares worth $1.31 millionTravere Therapeutics director Jeffrey A. Meckler exercised stock options on Sep. 10, 2026 for 20,000 commo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL7tql2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","BK4139","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","MEDI","RSPH","IEIH","LFSC","IDNA","SYNB","MRNX","GDOC","NVIB","TECB","IBB","FRTY","LABU","BMED","BK4588","XLVX","IYH","PSCH","BBP","BK4585","MRNY","TBXU","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666853924","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2666853924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666853924?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:40","pubTimestamp":1788964820,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Autolus Therapeutics (AUT...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-332?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-332?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","XBI","BK4585","LU0029874061.USD","HCSG","BK4581","BK4137","BK4139","XLV","LU0128526141.USD","LFSC","LABU","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EKG","BK4585","LFSC","GNMX","LU0320765992.SGD","PTH","HELX","GH","LU0109394709.USD","BK4196","GNOM","GDOC","BK4535","BK4588","LU0889565916.HKD","FFOX","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370307","title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370307","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370307?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:02","pubTimestamp":1788901342,"startTime":"0","endTime":"0","summary":"LivaNova director Brooke Story sells 2,300 shares for $187,270.14LivaNova director Brooke Story sold 2,300 ordinary shares on Sep. 4, 2026 at USD 81.42 each.Direct holdings fell to 7,488 ordinary shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1gkKlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIVN","LU2065169927.USD","LFSC","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","XPH","BME","IDNA","MEDX","WDNA","PJP","BBP","GNOM","FHLC","IBBJ","PBPH","BIB","JDOC","CURE","TBXU","PINK","IEIH","FTXH","MEDI","CANC","LFSC","HYLG","PTH","AZNH","CNCR","GNMX","GPCR","GSKH","IBBQ","PSCH","FXH","APXH","MNTL","MRNY","BBH","PSIL","LLYX","MDTX","NVIB","GDOC","JHMH","HRTS","PBE","RSPH","FBT","SBIO","SYNB","SURI","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","BK4588","LU0128526141.USD","XBI","BK4139","XLV","SYRE","BK4547","LABU","LFSC","BK4137","HCSG","BK4585","BCRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375642","title":"Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375642","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375642?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:35","pubTimestamp":1788874514,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics'  SPY003 met the primary endpoint in the phase 2 Skyline trial, reducing the Robarts Histopathology Index score by 10 points at week 12 in patients with moderately to severely active ulcerative colitis, the company said Tuesday.The anti-IL-23 therapy achieved a 20% clinical-remission rate, measured by modified Mayo Score, and a 30% endoscopic-improvement rate, while remaining well tolerated with a safety profile consistent with the IL-23 class, the company said.The results complete clinical proof-of-concept for all three components of Spyre's IBD strategy, with part B of the SKYLINE trial evaluating pairwise combinations now enrolling.Spyre expects topline SKYLINE part B induction data in 2027, with phase 2 SKYWAY results for SPY072 in psoriatic arthritis and axial spondyloarthritis expected in the fourth quarter of 2026, it added.Spyre Therapeutics shares were down 1.1% in premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","LENZ","SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665858375","title":"Video: Novartis slides after second recent drug development setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665858375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665858375?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872716,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BMED","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","GNMX","PTH","IE00BFTCPJ56.SGD","LU0154245756.USD","LU2065170008.USD","FFOX","GNOM","PJP","BK4137","LU2242646821.SGD","NBIX","BK4585","XBI","LU0029874061.USD","GH","BBH","GDOC","LU2242652126.USD","LFSC","BK4535","LU0889565916.HKD","HELX","PBE","IBB","LU1057294990.SGD","BK4588","IBBQ","LU0154245673.USD","BK4534","TBXU","IE0009355771.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","XLV","LU0109394709.USD","AMGN","IE0002141913.USD","LU0823416689.USD","BIB","LU0058720904.USD","BK4139","BK4533","LABU","LU0289739699.SGD","IE00B2B36J28.USD","BK4599","LU2468319806.SGD","EKG","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HRTS","FHLC","BME","FTXH","PJP","BIB","TBXU","PSCH","GSKH","CANC","AZNH","IBB","GNOM","NVIB","IBBQ","WDNA","FXH","PBE","CNCR","PBPH","PTH","LENZ","APXH","SBIO","LLYX","BBH","IDNA","CURE","GPCR","PINK","SURI","LFSC","JHMH","MEDX","IBBJ","XPH","SYNB","PSIL","MRNY","FBT","MDTX","MEDI","MNTL","JDOC","IBRN","HYLG","GNMX","BBP","RSPH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","FFOX","GNMX","LFSC","HELX","PTH","BK4551","BK4585","GNOM","BK4535","LU0109394709.USD","EKG","BK4196","GH","GDOC","LU0320765992.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320733","title":"Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320733?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:15","pubTimestamp":1788869740,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-12-week-induction-data-from-part-a-of-skyline-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","SYRE","LFSC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320564","title":"Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320564","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320564?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868896,"startTime":"0","endTime":"0","summary":"Spyre reports positive Phase 2 SKYLINE Part A induction data for UC drug SPY003, hits primary endpointSpyre Therapeutics reported positive 12-week induction results from Part A of its Phase 2 SKYLINE ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1KRyb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","SYRE","IE00BQXX3F31.USD","LU2210149790.SGD","BK4139","IE00BQXX3D17.EUR","NDAQ","IE00BGHQF748.EUR","BCDF","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","LFSC","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD","BK4588","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665544320","title":"Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665544320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665544320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320546","title":"Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320546?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320514","title":"Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320514?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA7PFYB1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}